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Major depression (MD) is a severe, life-
threatening, and highly prevalent psychiat-
ric disorder, predicted to soon become one
of the major causes of death worldwide.
Despite extensive investigations, the exact
mechanisms responsible for MD have not
been identified. This Overview focuses on
the role of stress in depression. It discusses
current advancements in biological psychi-
atry, neuroscience, and neuroendocrinolo-
gy, highlighting key findings presented in
the research papers included in the Special
Collection ‘‘Stress-Induced Depression and
Comorbidities: From Bench to Bedside,’’
published in this issue of PLoS ONE.T h e
Overview encompasses the problematic
diagnosis of MD, as well as preclinical
evidences linking genetic predisposition,
early life events and social factors, imbal-
anced HPA axis, molecular pathways
within the central nervous system, and
metabolic comorbidities with depression-
like disorders. It is emphasized how the link
between stress and depression can be
deeper than previously recognized, follow-
ing the description of a potentially common
depression subtype, named tentatively
‘‘stress-induced depression’’ (STRID). Due
to the inherent biological perspective un-
derlying the STRID concept, both preclin-
ical and clinical research will be pivotal in
clarifying the validity of this new subtype of
MD and in improving predictors for
treatment response, and will provide a
better basis for genetic studies as well as
stimulating new drug discovery programs.
Introduction
Major depression (MD) is a severe, life-
threatening, and widespread psychiatric
disorder having an incidence of about 340
million cases worldwide. MD ranks fifth
among leading causes of global disease
burden including developing countries, and
by year 2030 it is predicted to represent one
of the three leading causes of burden of
disease worldwide [1,2]. MD is also a risk
factor for cardiovascular and metabolic
diseases, and a major risk factor for suicide
[3]. Despite extensive investigations, the
exact mechanisms responsible for MD have
not been identified, and current therapeutics
are based on serendipitous discoveries rather
than on bench-to-bedside, targeted drug
discovery [4].Inaddition,althoughclinically
efficient antidepressant drugs do exist, the
situation is in many cases far from ideal.
Shortcomings such as low remission and/or
high treatment-resistance rates, slow onset of
action, side effects, and drug–drug interac-
tions merit the exploration of all plausible
agents that are effective, tolerable, and safe,
and that improve maintenance of wellness
[5–8]. Accordingly, there is an enormous
need for joint experimental efforts between
preclinical and clinical scientists.
Understanding MD in its etiology and
biologicalphenomenologicalcharacteristics
could improve its recognition and treat-
ment [8–11]. The present Overview high-
lights current trends in modern biological
psychiatry, neuroscience, and neuroendo-
crinology by discussing key aspects present-
ed in research papers included in the Special
Collection ‘‘Stress-Induced Depression and
Comorbidities: From Bench to Bedside,’’
published in this issue of PLoS ONE.
The Problematic Diagnosis of
Major Depression
Presently accepted diagnostic criteria
for MD [12] are five (or more) specific
symptoms having been present during the
same two-week period and representing a
change from previous functioning; at least
one of the symptoms should be either
depressed mood or loss of interest or
pleasure. Although their definition fol-
lowed rigorous statistical validating criteria
and years-long investigations, they are
often criticized as being subjective–quali-
tative rather than objective–quantitative
[13,14]. The current Diagnostic and Statisti-
cal Manual (DSM-IV) classification ignores
etiology, and distinguishes between bipolar
and unipolar conditions, and within the
unipolar group between cases with and
without melancholia, or with and without
psychotic symptoms, as well as atypical
depression. In addition, the current diag-
nostic criteria represent clusters of symp-
toms and characteristics of clinical courses
that do not necessarily describe homoge-
nous disorders and may rather reflect
common final pathways of different path-
ological processes [15]. MD is also a highly
heterogeneous disease. Subtypes of de-
pression may differ not only in etiology
and clinical picture, but also in clinical
response to medical treatments [15].
However, no past or present classification
includes biological criteria except for
changes in body weight or sleep parame-
ters [16]. Therefore, there is an urgent
need for neurological, biological, and
genetic data in future DSM classifications
[17]. Inclusion of biological diagnostic
criteria requires extensive investigation
on the biological correlates of MD as well
as on the implementation of mechanistic-
based investigations. In this respect, A ˚s-
berg and coworkers [18] and Schu ¨le and
coworkers [19] add to the current discus-
sion important biological correlates in MD
patients. Increased plasma monocyte che-
moattractant protein-1 (MCP-1), epider-
mal growth factor (EGF), and vascular
endothelial growth factor (VEGF) are
increased in a population of women under
prolonged psychosocial stress and can thus
be considered potential biomarkers for
screening and early interventions [18].
These data are particularly intriguing
because they extend a growing body of
evidence linking increased plasma concen-
tration of signaling molecules such as
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[13,20,21]. On the other hand, hypotha-
lamo–pituitary–adrenocortical (HPA)-axis
dysregulation is confirmed to be an
important parameter for treatment out-
come in MD by Schu ¨le and coworkers
[19], although dysfunction of the HPA
system as determined by the classical
dexamethasone (DEX)/corticotrophin re-
leasing hormone (CRH) test as well as with
other neuroendocrine assays, seems to be
neither a necessary nor a sufficient deter-
minant for acute treatment response. Of
interest from a biological perspective,
Cze ´h and coworkers [22] recently ob-
served that chronic tianeptine treatment
may reverse neurobiological alterations
associated with chronic psychosocial stress
in male tree shrews without an improve-
ment in HPA functions (see also [23]).
Genetic Predisposition
Although no single gene could be
responsible for a complex and multifacto-
rial disorder like MD, association and
pharmacogenetic studies identified a num-
ber of loci associated with vulnerability to
MD or antidepressant efficacy [8,10,24–
26]. In parallel, increasing evidences
report gene6environment (G6E) effect
in MD, with stress often representing the
key environmental trigger of MD onset in
vulnerable individuals [27]. Preclinical
studies are ongoing to elucidate specific
genes and environmental context that
could precipitate psychopathologies [28].
An alternative approach by Touma and
coworkers [29] is described here: They
selected for seven generations of mice
based on their corticosterone reactivity to
an environmental challenge. They dem-
onstrate that individuals selected to be
high responders show blunted circadian
rhythmicity of HPA-axis hormones, be-
havioral hyperactivity, and changes in
rapid eye movement (REM) and non-
REM sleep, as well as slow wave activity,
indicative of reduced sleep efficacy. Con-
sidering the incidence of disturbed HPA
axis and sleep disorders in MD patients,
these selected mouse lines may offer a new
important experimental tool.
G6E effects are easily accessible for
preclinical investigations, and the elevated
number of inbred strains of mice (i.e.,
animals showing almost null heterozygosis)
available offers a powerful experimental
tool. In this respect, Schweizer and
coworkers [30] further clarify how differ-
ent inbred strains of mice can have very
different vulnerabilities to the chronic mild
stress model of depression in both behav-
ioral and physiological parameters, thus
offering an invaluable tool to understand-
ing G6E interaction in stress-induced
disturbances.
A Biological Pathogenesis: The
Stress Model and HPA Axis
Activity
Stress is usually defined as a state of
disturbed homeostasis inducing somatic
and mental adaptive reactions, globally
defined as ‘‘stress response,’’ aiming to
reconstitute the initial homeostasis or a
new level of homeostasis after successful
adaptation, i.e., allostasis [31–34]. There
is wide consensus and support from
preclinical and clinical data that stress
exposure conceivably plays a causal role in
the etiology of MD and depression-like
disorders [11,27,31,34]. However, no spe-
cific mechanism linking stress exposure
and stress response to the occurrence of
MD has yet been fully elucidated. Grow-
ing evidence indicates several classical
candidates, including neurotransmitters
and neuropeptides, as well as conceptually
novel immune and inflammatory media-
tors, as likely intermediate links between
stress exposure, depressive symptoms, and
MD [9,21,34–38]. Related to the latter,
A ˚sberg and coworkers [18] discuss in their
paper in this Collection a potential role for
some inflammatory mediators in a cohort
of patients under prolonged psychosocial
stress, providing further epidemiological
support (results discussed above in this
Overview).
One of the hallmarks of the stress
response has long been considered the
activation of the HPA axis. Hypothalamic
CRH activation is a pivotal signaling
molecule in the regulation of the HPA
axis in particular and of the stress response
in general. Therefore, comprehension of
the mechanism responsible for the nega-
tive feedback regulation of CRH is of
paramount importance. In the present
Collection, van der Laan and coworkers
[39] demonstrate that the timing of
glucocorticoid receptors (GR) activation
determines the effective repression of the
cAMP-induced transcription of the CRH
gene, thus clarifying that in vivo a critical
time window may exist for effective
repression of the CRH gene and HPA
axis by glucocorticoids.
Knowledge on the functioning of the
HPA axis under acute or chronic chal-
lenge is also a key to understanding the
intimate link between stress response and
the pathogenesis of depression [40]. In-
deed, in all MD syndromes, a certain
degree of HPA-axis disturbance is often
present, visible either at the baseline or
with functional tests. Despite the fact that
observed changes of HPA regulation are
so far not specific for the diagnosis of
depression or for any of its clinical
syndromes [8], altered HPA-axis parame-
ters are considered important biomarkers,
particularly in preclinical studies. In-
creased circulating hormones such as
adrenocorticotropic hormone (ACTH)
and cortisol/corticosterone or increased
adrenal gland weight are considered
biomarkers of stress response in preclinical
models [41], including in several papers in
this Collection [19,29,42–46]. Despite the
bulk of data available, surprisingly current
knowledge has not yet been developed to a
point where HPA-axis reactivity can be
rationally exploited for targeted drug
treatment, as opposed to the major
achievements of drugs targeting the
CRH receptors [47]. Present data offer
reliable experimental tools to stimulate
future drug discovery programs [48].
Behavioral Neuroscience
The DSM-IV identifies specific behav-
ioral and cognitive diagnostic criteria for
MD patients. Among these, depressed
mood, anhedonia, locomotor disturbanc-
es, and anxiety are accessible for preclin-
ical investigation, while others such as
feelings of worthlessness and thoughts of
death or suicide cannot be reliably mim-
icked in animal models. A number of
animal models have been developed and
validated [11,38,49–51]. In particular,
models involving a chronic (i.e., continu-
ous exposure to a threatening stimulus for
a significant amount of time, usually
weeks) or intermittent (i.e., daily short
exposure to a threat for subsequent days)
exposure to negative stressful events can
be considered the most effective in mod-
eling MD-associated behavioral and phys-
iological disturbances (but see [52]). In line
with this conclusion, the preclinical papers
included in the Special Collection of PLoS
ONE make use of chronic or intermittent
models of stress [30,42–45]. Furthermore,
papers in the Collection also describe animal
models that are increasingly being regard-
ed as the most promising to model
etiological factors and key features of
MD patients, i.e., i) models in which the
threatening stimulus is social in nature
[42,46], ii) models in which exposure to
stressful stimuli occurs in the early post-
natal or juvenile age [44,46].
From a nosological point of view,
original research presented in the Collection
further clarifies that at least some behav-
ioral disturbances present in MD diagnos-
tic criteria can be reliably induced and
Stress & Depression
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models, including for anhedonia [30],
locomotor disturbances [29,42,44,53],
anxiety [44,53], sleep pattern [29], and
learning/memory [44,53]. Of main inter-
est is the experimental evidence [30] that a
shift in the circadian rhythm induced by
overnight illumination is the single most
important experimental factor influencing
the intake of a sweetened solution, which is
the currently accepted animal equivalent
of evidence of anhedonia [54]. Further-
more, Ilin and Richter-Levine [44] show
that daily exposure to a stressful stimulus
for three consecutive days at a juvenile age
(named juvenile stress, JS), determines
long-lasting behavioral and motivational
effects in rats, i.e., increased anxiety, lower
exploratory drive, and increased learned
helplessness. On the contrary, housing JS
rats in an enriched environment complete-
ly abolished JS-induced behavioral effects.
A similar ameliorating effect on stress
coping has also been determined by
Collins and coworkers [53], by exposing
rats to a different form of environmental
enrichment, i.e., home cage presence of a
running wheel which induces in rodents
spontaneous physical exercise. Exercised
rats show increased behavioral coping and
reduced anxiety and depression-like be-
haviors in the open field test and in the
forced swimming test when compared
with sedentary rats.
Molecular Neuroscience
In the postgenomic era, high-throughput
techniques allow the identification of genes
overexpressed or downregulated in selected
brain regions after chronic stress exposure
or in MD. Following these observations,
researchers now aim at translating omics
evidences into experimentally based results
(based on on purpose experimental designs).
For example, the ‘‘sequenced treatment
alternatives to relieve depression’’
(STAR*D) clinical trial identified several
loci associated with response to anti-
depressants and suicidal ideation in MD
patients [55,56]. Among these is the gene
encoding for a class of ionotropic glutamate
receptors known as kainate receptors (KA).
Hunter and coworkers [45]now report that
KA1 subunit mRNA is selectively modu-
lated by stress- and HPA-axis activity in the
dentate gyrus and CA3 region of the
hippocampal formation. Another fruitful
approach follows the identification of
potential biomarkers in postmortem brain
tissue of MD patients. A recent study found
in the prefrontal and parieto-occipital
cortex of MD patients an altered level of
the L1-cell adhesion molecule (L1-CAM)
[57]. Ilin and Richter-Levin [44] firstly
demonstrate that juvenile stress in rats is
able to upregulate L1-CAM expression in
the basolateral amygdala and the thalamus
(in parallel with behavioral disturbances
described above), and secondly they prove
that environmental enrichment is able to
reverse stress-induced alterations. A final
example concerns the role of membrane
glycoprotein M6a in stress and neuroplas-
ticity. M6a mRNA was found to be
upregulated in the hippocampus of both
mice and tree shrews under chronic stress
[58,59]. Cooper and coworkers [43] now
establish for the first time that only a splice
variant, M6a-Ib, is modulated in a region-
ally dependent manner, i.e., downregulated
in the dentate gyrus granule neurons and in
CA3 pyramidal neurons while upregulated
in the medial prefrontal cortex.
According to the examples above, it can
be concluded that changes in gene expres-
sion and their association with behavioral
traits or psychopathologies remain among
the more powerful experimental tools to
uncover the mechanisms leading to a
brain disorders. In addition, recent find-
ings demonstrate that complex ‘‘epigenet-
ic’’ mechanisms, which regulate gene
activity without altering the DNA code,
have long-lasting effects within mature
neurons [60]. An example of the former
is presented by Collins and coworkers
[53], who establish that histone (H3)
phospho-acetylation and c-Fos immunore-
activity increase in the dentate gyrus upon
exposure to a novel environment or to
forced swimming and that their expression
is further augmented in exercised rats.
Another fruitful research area in bio-
logical psychiatry is the link between
neural plasticity, MD, and antidepressants
[9,13,32,61]. In particular, neurogenesis in
the granular layer of the dentate gyrus is
impaired by stress exposure and increased
by other environmental factors including
environmental enrichment or exercise
[9,61]. Of main interest was the demon-
stration that hippocampal neurogenesis is
required for the beneficial effect of some
but not all antidepressant classes [62–64].
Although impaired neurogenesis could not
be confirmed in a human cohort of MD
patients [65], the study of adult hippo-
campal neurogenesis in MD has benefited
tremendously from the attention it has
received, and results will ultimately dem-
onstrate its role in the etiology and/or
treatment of MD [60]. Oomen and
coworkers [46] now demonstrate that
maternal deprivation in rats at postnatal
day 3, which induces a transient increase
of maternal care, also determines impaired
neurogenesis in the dentate gyrus (DG) of
female rats, while increasing neurogenesis
in male rats. Therefore, early environment
may have a critical influence on establish-
ing long-held sex differences in neural
plasticity. This finding is particularly
interesting because MD incidence in
women is about twice that for men [66].
Metabolic Functions
In addition to neuroanatomical chang-
es, MD is also associated with severe
vegetative and biological disturbances,
including sleep and eating disorders, body
weight changes, and neuroendocrine ab-
normalities. The DSM-IV indicates as
diagnostic criteria increased or diminished
appetite/body weight which should repre-
sent a change from pre-MD onset. Most
animal models including several discussed
in the present Collection [30,43–45] de-
scribe stress-associated weight loss, which
has long being considered a face-validity
criterion for a valid animal model of MD
[67]. Until recently there was a paucity of
animal models of chronic stress-induced
weight gain. Bartolomucci and coworkers
[42] now report a mouse model of social
subordination stress with behavioral de-
pression-like responses and neuroendo-
crine disturbances, which also determine
hyperphagia, weight gain, and increased
vulnerability to obesity. In addition, an-
other study in the present Collection [46]
reports that maternal deprivation deter-
mined increased weight gain in juvenile
rats when compared with undisturbed
controls. These data offer new experimen-
tal tools to investigate the link between
mood disorders and metabolic functions.
In this respect it is remarkable that obesity
is often found in comorbidity with MD
and particularly so with the atypical
depression subtype [68], while clinical
efficacy of antidepressants is reduced in
obese individuals [69]. Accordingly, there
is a great need to rule out the mechanism
responsible for stress-induced positive or
negative energy balance in different ani-
mal models as well as in MD patients.
‘‘Stress-Induced Depression’’
(STRID): A New Depression
Subtype?
The notion that stress may cause
depression has been an underlying con-
cept in the choice of papers included in the
PLoS ONE Collection discussed here. The
link between stress and depression is not
novel, and several authors have aimed at
identifying new subtypes of depression
based on their functional link with stress
exposure (e.g., [70–72]). Of special interest
Stress & Depression
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tially common depression subtype, named
tentatively ‘‘stress-induced depression’’
(STRID), recently described in Sweden
by A ˚sberg and coworkers [71]. A dramatic
increase in the number of workers on long-
term sick leave was observed between the
years 1997 and 2003 (Statistics Sweden,
2004; http://www.scb.se). Studies of con-
secutive cases with psychiatric diagnoses
culled from the databases of two large
Swedish insurance companies showed that
about 80% of patients met DSM-IV
criteria for MD (A ˚sberg et al., unpublished
data). The depression episodes were mild
to moderate (MADRS ,20), and accom-
panied by significant working memory
impairment [71]. Follow up showed that
STRID tended to have a prolonged
course, and that the patients often re-
mained in a state of exhaustion after the
depressive symptoms had remitted. Typi-
cally, the remaining clinical picture was
one of deep mental and physical fatigue,
disturbed and non-restorative sleep, irrita-
bility, perceptual hypersensitivity, emo-
tional liability, and pronounced cognitive
disturbances (mainly memory and concen-
tration problems). A closer examination of
the case histories revealed that a majority
was clearly induced by psychosocial stress,
either at the workplace or often in
combination with stress factors in the
family. This was confirmed by data
obtained in a cohort of almost 5,000
Swedish workers on long-term sick leave
with a psychiatric diagnosis [73]. Findings
are consistent with the life event stress
literature showing that specific, enduring
work-related stressful experiences contrib-
ute to depression [74]. From an endocrine
standpoint, disturbances of the HPA axis
may be distinctive pathophysiological fea-
tures of this depression subtype. HPA-axis
hyper-reactivity has long been known and
considered a classical feature of depres-
sion, particularly with the severe, melan-
cholic type. An opposite situation, i.e.,
HPA-axis hypo-reactivity was found in-
stead in STRID patients [71]. In addition
to the HPA-axis disturbance, the STRID
subtype of MD is expected to be linked to
different neurobiological, immunological
[18], and metabolic features, thus requir-
ing joint forces between preclinical and
clinical research.
Overall, the studies presented in this
Special Collection of PLoS ONE propose an
integrated effort on how to move in the
direction of joint studies. Both preclinical
and clinical research will be pivotal in
clarifying the validity of this new subtype
of MD, in improving predictors for
treatment response, and in providing a
better basis for genetic studies, as well as in
stimulating new drug discovery processes.
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